Selected equity rounds joined since 2023; amounts show the whole round
10 minority investmentsrounds joined worth $2.5B in total
5 minority investmentsrounds joined worth $719M in total
20232024202520262027Eli LillyFlare Therapeutics · Headquarters: United States · Series B · $123M round · Mar 2023 · Bringing an entirely different approach to decipher the biology of transcription factors to develop small molecule medicinesFlare TherapeuticsSeries B · $123M round · Mar 2023Mariana Oncology · Headquarters: United States · Series B · $175M round · Sep 2023 · Delivering innovative, safe and effective radiopharmaceutical care for solid cancersMariana OncologySeries B · $175M round · Sep 2023Capstan Therapeutics · Headquarters: United States · Series B · $175M round · Mar 2024 · Advancing cell engineering to develop therapeutics for a broad range of diseasesCapstan TherapeuticsSeries B · $175M round · Mar 2024Aktis Oncology · Headquarters: United States · Series B · $175M round · Sep 2024 · Biotechnology company discovering and developing a novel class of targeted radiopharmaceuticalsAktis OncologySeries B · $175M round · Sep 2024Superluminal Medicines · Headquarters: United States · Series A · $120M round · Sep 2024 · Generative biology and chemistry company revolutionizing the speed and accuracy of how medicine is createdSuperluminal MedicinesSeries A · $120M round · Sep 2024Strand Therapeutics · Headquarters: United States · Series B · $153M round · Aug 2025 · Biotechnology platform intended to create gene therapies powered by synthetic biologyStrand TherapeuticsSeries B · $153M round · Aug 2025Innovent Biologics · Headquarters: China · Post-IPO equity · $350M round · Feb 2026 · Innovent Biologics is a biopharmaceutical company developing and manufacturing monoclonal antibodiesInnovent BiologicsPost-IPO equity · $350M round · Feb…Cabaletta Bio · Headquarters: United States · Post-IPO equity · $150M round · May 2026 · biopharmaceutical company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases. Cabaletta BioPost-IPO equity · $150M round · May…Resilience · Headquarters: United States · Growth equity · $750M round · Jul 2026 · Broadening access to complex medicines and protecting biopharmaceutical supply chains against disruptionResilienceGrowth equity · $750M round · Jul 2…AdvanCell · Headquarters: Australia · Series D · $315M round · Jul 2026 · Radiopharmaceutical firm that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatmentAdvanCellSeries D · $315M round · Jul 2026Novo NordiskElevateBio · Headquarters: United States · Series D · $401M round · May 2023 · Accelerating the rate of innovation and success in cell and gene therapy with a disruptive capital-efficient modelElevateBioSeries D · $401M round · May 2023Tanai Therapeutics · Headquarters: Belgium · Seed · $3.4M round · Sep 2024 · Oral therapeutics for obesity targeting energy expenditureTanai TherapeuticsSeed · $3.4M round · Sep 2024Eikonizo Therapeutics · Headquarters: United States · Early-stage VC · undisclosed · Dec 2024 · Developing therapies to improve the treatment of human disease, specifically neurodegenerative diseasesEikonizo TherapeuticsEarly-stage VC · undisclosed · Dec…Aspect Biosystems · Headquarters: Canada · Series B · $115M round · Jan 2025 · Commercializing cutting-edge bioprinting technologiesAspect BiosystemsSeries B · $115M round · Jan 2025Soufflé Therapeutics · Headquarters: United States · Seed · $200M round · Oct 2025 · Targeted siRNA medicines for genetic and autoimmune diseasesSoufflé TherapeuticsSeed · $200M round · Oct 2025

Swipe sideways to see the whole timeline →

Source: Dealroom.co · company announcements